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Abstract
Increasing evidence has suggested a critical role for endothelial-to-mesenchymal transition (EndoMT) in a variety of
pathological conditions. MicroRNA-200c-3p (miR-200c-3p) has been implicated in epithelial-to-mesenchymal
transition. However, the functional role of miR-200c-3p in EndoMT and neointimal hyperplasia in artery bypass
grafts remains largely unknown. Here we demonstrated a critical role for miR-200c-3p in EndoMT. Proteomics
and luciferase activity assays revealed that fermitin family member 2 (FERM2) is the functional target of miR-
200c-3p during EndoMT. FERMT2 gene inactivation recapitulates the effect of miR-200c-3p overexpression on
EndoMT, and the inhibitory effect of miR-200c-3p inhibition on EndoMT was reversed by FERMT2 knockdown. Fur-
ther mechanistic studies revealed that FERM2 suppresses smooth muscle gene expression by preventing serum
response factor nuclear translocation and preventing endothelial mRNA decay by interacting with Y-box binding
protein 1. In a model of aortic grafting using endothelial lineage tracing, we observed that miR-200c-3p expression
was dramatically up-regulated, and that EndoMT contributed to neointimal hyperplasia in grafted arteries. MiR-
200c-3p inhibition in grafted arteries significantly up-regulated FERM2 gene expression, thereby preventing
EndoMT and reducing neointimal formation. Importantly, we found a high level of EndoMT in human femoral arteries
with atherosclerotic lesions, and that miR-200c-3p expression was significantly increased, while FERMT2 expression
levels were dramatically decreased in diseased human arteries. Collectively, we have documented an unexpected role
for miR-200c-3p in EndoMT and neointimal hyperplasia in grafted arteries. Our findings offer a novel therapeutic
opportunity for treating vascular diseases by specifically targeting the miR-200c-3p/FERM2 regulatory axis.
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great
Britain and Ireland.
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Introduction
Although coronary artery bypass grafting (CABG) is
one of the most successful procedures for treating
patients with coronary artery disease (CAD), and has
been recommended as the gold standard for patients with
multiple-vessel disease [1,2] and/or left main CAD
regardless of the patient’s SYNTAX score (low, inter-
mediate or high) [3–5], long-term survival rates in these
patients are still poor and strongly limited by the devel-
opment of graft vasculopathy or failure due to neointi-
mal lesion formation. Neointimal smooth muscle cell
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(SMC) hyperplasia is the key pathophysiological mech-
anism of vascular diseases including vascular graft reste-
nosis [6]. Despite decades of investigations, the origin of
neointimal cells remains controversial, with increasing
evidence pinpointing a contribution of medial SMCs,
stem/progenitor cells [7,8], and endothelial–
mesenchymal transition (EndoMT) [9–13]. EndoMT is
a transition process characterized by loss of cell–cell
adhesions and changes in cell polarity, with reduced
expression of endothelial cell (EC) markers but
increased expression of mesenchymal cell (or SMC-like)
markers. The resultant cells acquire myofibroblast-like
characteristics with contractile function, enhanced
migratory and proliferative phenotype, and increased
extracellular matrix production. Meanwhile, they lose
EC functional characteristics with an impaired anti-
thrombogenicity and angiogenesis [11,14,15].
Accumulating evidence from preclinical studies and
histological observations in humans has provided clear
evidence that EndoMT not only plays a fundamental role
in normal embryonic developmental processes [14–16]
but also contributes to a variety of pathological condi-
tions including ventricular diastolic dysfunction [17],
atherosclerosis [13,18] and atherosclerotic plaque insta-
bility [10], pulmonary arterial hypertension [9], vascu-
lar graft remodelling [12], vascular and valvular
calcifications [19,20], and tumour progression, among
others [15,16,21–24]. Therefore, exploring the underly-
ing molecular mechanisms of EndoMT is key to devel-
oping novel therapeutic strategies aimed at treating
these conditions. Although multiple intercellular mech-
anisms and signal pathways have been suggested to
govern EndoMT [15,16,18,21,22,25,26], the exact
molecular mechanisms involved in cardiovascular path-
ogenesis that occur as a result of EndoMT remain
obscure.
MicroRNAs (miRNAs) are short (20–23 nt) and con-
served non-coding RNAs with profound roles in cardio-
vascular diseases. A handful of miRNAs have been
reported to play a role in regulating EndoMT by target-
ing one or multiple EndoMT-associated genes
[15,16,21,26,27]. miRNA-200c-3p (miR-200c-3p)
belongs to the miR-200 miRNA cluster. The miR-200
family is overwhelmingly linked with epithelial–
mesenchymal transition (EMT) and its inverse processes
[28]. Later studies also support the involvement of this
miRNA family in EndoMT [16]. Since controversial
and cellular context-dependent roles for the miR-200
family in EMT or EndoMT have been widely documen-
ted [16,29], more studies are needed to focus on individ-
ual members of the miR-200 family to elucidate their
specific role in these pathological conditions. In particu-
lar, miR-200c-3p has been widely implicated in cardio-
vascular development and diseases [30]. Importantly,
we have demonstrated previously a critical role for
miR-200c-3p in EC differentiation from human embry-
onic stem cells [31]. However, the functional implication
of this miRNA in EndoMT and vascular grafting-
induced neointimal SMC hyperplasia remains elusive.
In the current study, we demonstrate that miR-200c-3p
promotes EndoMT by partially targeting fermitin family
member 2 (FERM2), and therefore, modulation of the
miR-200c-3p/FERM2 regulatory axis in vascular grafts
represents a novel therapeutic approach for preventing
vascular graft failure in patients with CABG.
Materials and methods
Animals and mouse experiments
Cdh5-CreERT2 × Rosa26-tdTomato mice were gener-
ated by crossing Tg(Cdh5-CreERT2) with
Rosa26-CAG-LSL-cas9-tdTomato mice (both are on a
C57BL/6J background and were obtained from Gem-
pharmatech, Jiangsu, PR China). Tamoxifen (T5648;
Merck, Haverhill, UK) was dissolved in corn oil and
administered by gavage (0.15 mg/g body weight, four
times) to male Cdh5-CreERT2 × Rosa26-tdTomato
mice to induce Cre recombinase activity and tdTomato
expression as described in previous studies [8,32]. After
a 2-week washout, thoracic aortic segments were har-
vested and randomly allocated to different experimental
groups. Animal husbandry and all experimental proce-
dures were approved and performed in accordance with
the guidelines of the Institutional Animal Care and Use
Committee of The First Affiliated Hospital of Chong-
qing Medical University or Queen Mary University of
London (PB508B78D). In addition, the principles gov-
erning the care and treatment of animals, as stated in
the Guide for the Care and Use of Laboratory Animals
published by the National Academy of Sciences (8th
edn, 2011), were followed at all times during this study.
All mice were euthanized by placing them under deep
anaesthesia with 100% O2–5% isoflurane, followed by
cervical dislocation.
Mouse aortic isograft transplantation was performed
as described previously [33,34]. The procedures for
local miR-200c-3p inhibition in the grafted aortas were
similar to that described in our previous study [35] with
some modifications. In brief, immediately after harvest,
50–60 μl of DMEM containing vehicle (mock transfec-
tion, sham), control scrambled locked nucleic acid
(LNA) modified oligonucleotides (LNA-SCR), or
LNA-miR-200c-3p per vessel was randomly injected
into the arteries, followed by a 30-min incubation for
local transfection of endothelium. After that, aortic seg-
ments were transplanted into the carotid artery using
end-to-end anastomosis.
Statistical analysis
Each experiment was performed in at least five biologi-
cal replicates, and all values are expressed as
mean  standard error of the mean (SEM). Statistical
analysis as specified in the figure legends and prepara-
tion of plots was performed using GraphPad Prism
8 (GraphPad Inc, San Diego, CA, USA). In brief, the
Kolmogorov–Smirnov (K–S) normality test was used
for checking the normality of the data. Two-tailed
unpaired Student’s t-test was used for comparisons
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between two groups, or one (or two)-way analysis of
variance (ANOVA) with a Tukey’s post hoc test was
applied when more than two groups were compared.
p < 0.05 was considered statistically significant.
Details are available in Supplementary materials
and methods for Antibodies used, Cell culture and
induction of EndoMT, MiR-200c-3p inhibitor transfec-
tion, Human FERMT2 3’-UTR clone and miR-200c-3p
binding sites mutation, Human SMC gene reporter plas-
mids and related SRF binding site mutants, Transient
transfection and luciferase activity assays, FERMT2
shRNA lentivirus, Generation of miR-200c-3p overex-
pression pseudo-viral particles, Cell proliferation
(CCK-8) assays, Transwell migration assays, Tube
formation, Western blotting, Proteomics studies and
data analysis, Reverse transcription–quantitative real-
time PCR (RT-qPCR), miProfile™ Custom miRNA
qPCR Arrays analysis, Chromatin immunoprecipitation
(ChIP) assays, RNA immunoprecipitation (RIP) assays,
Aortic grafting experiments, Morphometric analysis
and quantification of lesion formation, Immunofluores-
cence analysis, Aortic cell sorting, and Proximity liga-
tion assays (PLAs).
Results
miRNA expression during EndoMT
Human umbilical vein endothelial cells (HUVECs) or
aortic endothelial cells (HAoECs) could be stimulated
to undergo EndoMT by treating them with a cytokine
combination of transforming growth factor-β1 (TGFβ1)
and interleukin-1β [36] or tumour necrosis factor alpha
(TNFα) [37]. HUVECs treated with these two cytokines
gradually underwent a clear morphological transition,
adopting a more SMC or mesenchymal appearance over
the 8-day treatment (supplementary material,
Figure S1A). Coincident with this morphological transi-
tion, HUVECs treated with TGFβ1/TNFα displayed a
significantly decreased expression of EC markers
(PECAM1, CDH5, NOS3, VWF, and KDR) (supplemen-
tary material, Figure S1B), but a dramatically increased
expression of mesenchymal/SMC markers (SMαA/
ACTA2, SM22α/TAGLN, SMTN, CDH2, DDR2, and
FSP1/S100A4) (supplementary material, Figure S1C) and
a host of EndoMT-associated regulators (SNAI1, SNAI2,
TWIST1, and TWIST2) (supplementary material,
Figure S1D). Such changes were further confirmed at pro-
tein levels (supplementary material, Figure S1E,F). These
data collectively confirmed that TGFβ1/TNFα combina-
tional treatment could induce EndoMT. A customized
miRNA RT-qPCR Array analysis (GeneCopoeia,
Rockville, MD, USA) was conducted to identify potential
miRNA candidates governing the EndoMT process.
Nineteen and 33 miRNAs were significantly up- and
down-regulated during EndoMT, respectively (supplemen-
tary material, Figure S2). Interestingly, we found that three
of the miR-200 miRNA family members (miR-200a,
-200b, and -429) were significantly down-regulated during
EndoMT, but the opposite was observed with miR-200c-3p
expression (supplementary material, Figure S2). This find-
ing was further confirmed using RT-qPCR analysis
(Figure 1A).
Effect of miR-200c-3p on EndoMT
To study the potential effect of miR-200c-3p on
EndoMT, miR-200c-3p loss/gain-of-function experi-
ments were conducted in HUVECs undergoing
EndoMT. Data from RT-qPCR analyses confirmed that
a panel of EC and mesenchymal/SMC genes were
significantly up-regulated and down-regulated by miR-
200c-3p inhibition, respectively (Figure 1B). A similar
inhibitory effect was observed with EndoMT-associated
mediators (Figure 1B). Western blot assays showed that
miR-200c-3p knockdown increased ECmarker proteins,
but decreased SMC/mesenchymal marker and EndoMT
regulatory proteins (Figure 1C). Functionally, miR-
200c-3p inhibition in HUVECs undergoing EndoMT
resulted in a cellular morphological appearance resem-
bling normal ECs (supplementary material,
Figure S3A), decreased cell proliferation (supplemen-
tary material, Figure S3B) and migration (supplemen-
tary material, Figure S3C), and increased angiogenesis
(supplementary material, Figure S3D,E). Conversely,
the opposite effects were observed when miR-200c-3p
was overexpressed in HUVECs undergoing EndoMT
(supplementary material, Figures S4 and S5). Impor-
tantly, a similar role for miR-200c-3p in EndoMT was
also observed in HAoECs (supplementary material,
Figure S6).
Proteomics analysis to uncover the potential target
genes of miR-200c during EndoMT
Label-free quantitative proteomics analyses were con-
ducted to search for the potential target genes of miR-
200c-3p during EndoMT. As shown in supplementary
material, Figure S7A, 87 proteins were found to be sig-
nificantly modulated by miR-200c-3p overexpression.
Since promoting RNA decay and controlling target gene
translational repression is the fundamental regulatory
mechanism for most of the miRNAs, the proteins
down-regulated by miR-200c-3p overexpression repre-
sent possible target genes of miR-200c-3p in EndoMT.
Interestingly, GO term enrichment analysis of the pro-
teins regulated by miR-200c-3p during EndoMT
showed that E-box/cadherin binding, morphogenesis/
development of aortic and heart valve and endocardial
cushion, mesenchyme morphogenesis, cardiovascular
system development and angiogenesis, cellular develop-
ment, cell migration/adhesion, cell–cell junction organi-
zation/assembly, and regulation of metabolic processes
were the highly enriched biological processes and/or
molecular functions (supplementary material,
Figure S7B,C). These observations further supported a
role for miR-200c-3p in EndoMT. Importantly, by using
several computational algorithmic databases, we have
identified one or more miR-200c-3p binding sites within
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Figure 1.miR-200c-3p inhibition prevents EndoMT. (A) Expression levels of the miR-200 family during EndoMT. HUVECs were incubated with
5 ng/ml TGFβ1 and 5 ng/ml TNFα for the indicated times to induce EndoMT. (B, C) Inhibition of miR-200c-3p prevents EndoMT. HUVECs were
transfected with reagent control only (Ctrl), a scrambled negative control miRNA inhibitor (SCR inhibitor) or miR-200c-3p inhibitor (miR-
200c inhibitor), respectively. Transfected cells were incubated with 5 ng/ml TGFβ1/TNFα for 4 days. Total RNAs and proteins were harvested
and subjected to RT-qPCR (B) and western blot (C) analysis, respectively. Left panel in C: representative images; right panel: quantitative
results of five independent experiments. The data presented here are mean  SEM of five (n = 5) independent experiments. *p < 0.05,
**p < 0.01, or ***p < 0.001 (versus D0 or Ctrl/SCR; one-way ANOVA with a Tukey’s post hoc test).
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the 3’-UTR of 24 (out of 41) genes whose protein
expression levels were down-regulated by miR-200c-
3p overexpression. As such, these proteins likely repre-
sent good candidates as functional direct target genes
of miR-200c-3p in EndoMT.
FERM2 is a novel target of miR-200c-3p in EndoMT
As shown in a volcano plot (Figure 2A), fermitin family
member 2 (FERM2 or FERMT2) has been clearly sig-
nalled out as the most meaningful and important target
gene of miR-200c-3p in EndoMT. Data from western
blotting (Figure 2B) and RT-qPCR (Figure 2C) analyses
further confirmed the proteomics data that miR-200c-3p
overexpression significantly decreased FERM2 protein
as well as mRNA expression levels. There are two con-
served miR-200c-3p binding sites within the 3’-UTR
of FERMT2, as predicted using the computational algo-
rithm miRanda (Figure 2D). Luciferase assays showed
that the luciferase activity of the construct harbour-
ing the wild-type FERMT2 3’-UTR was dramatically
decreased by miR-200c-3p overexpression (Figure 2E).
Importantly, luciferase activity assays with miR-200c-
3p binding site single (BS1mutor BS2mut) or combina-
tional (BS1/2mut) mutant reporters demonstrated that
both binding sites are required for FERMT2 gene repres-
sion mediated by miR-200c-3p (Figure 2E). Collec-
tively, these data confirm that FERMT2 is a true
mRNA target of miR-200c-3p in EndoMT.
FERMT2 gene suppression is required for miR-200c-
3p-mediated EndoMT
To explore the mechanistic link between miR-200c-3p
and FERM2 in EndoMT, co-transduction experiments
as indicated in the figures were conducted in HUVECs
undergoing EndoMT. RT-qPCR data showed that the
expression level of FERMT2was significantly increased
bymiR-200c-3p inhibition, but such induction was abol-
ished by FERMT2 knockdown in the presence of the
miR-200c-3p inhibitor (supplementary material,
Figure S8A). However, miR-200c-3p expression was
not regulated by FERMT2 gene inactivation (supple-
mentary material, Figure S8A), further confirming that
the FERMT2 gene is a downstream target of miR-
200c-3p. Importantly, RT-qPCR data showed that
miR-200c-3p inhibition and FERMT2 knockdown acti-
vated and inhibited EC marker gene expression, respec-
tively, and that EC gene activation by miR-200c-3p
inhibition was blunted by FERMT2 knockdown (supple-
mentary material, Figure S8B). The opposite effect was
observed with mesenchymal/SMC genes in response to
the same treatment (supplementary material,
Figure S8C).
FERM2 regulates SMC gene expression through a
transcriptional repression mechanism
Since our data show that both SMC genes (ACTA2 and
TAGLN) were activated by FERMT2 knockdown (sup-
plementary material, Figure S8C), we decided to
investigate how SMC gene expression was inhibited by
FERM2 during EndoMT. Data retrieved from multiple
protein–protein interaction (PPI) databases
(e.g. BioGrid, CORUM, IntAct, MINT, and/or
STRING) showed a very complicated FERM2 PPI net-
work (supplementary material, Figure S9). Among
them, serum response factor (SRF) represents a very
interesting candidate protein as SRF is a well-known
master transcriptional factor controlling the expression
of a host of SMC genes. We found that the gene expres-
sion level of SRF was not regulated by FERMT2 knock-
down in HUVECs undergoing EndoMT (Figure 3A).
Double immunofluorescence staining showed that while
SRF was mainly co-localized with FERM2 within the
cytoplasm of control cells, FERMT2 knockdown (sup-
plementary material, Figure S10A) or miR-200c-3p
overexpression (supplementary material, Figure S10B)
promoted SRF accumulation within the nuclei. Impor-
tantly, the PLA results revealed in situ interactions in
control cells between FERM2 and SRF within the cyto-
plasm, while such interactions were dramatically
decreased in cells with FERMT2 knockdown
(Figure 3B). Moreover, luciferase activity assays
showed that the promoter activity of both SMC genes
(ACTA2 and TAGLN) was significantly increased by
FERMT2 knockdown, while such induction disappeared
once the SRF binding elements were mutated in these
reporters (Figure 3C). Furthermore, ChIP assays con-
firmed the direct binding of SRF and SMC gene pro-
moters, which was further enhanced by FERMT2
knockdown in HUVECs undergoing EndoMT
(Figure 3D). Collectively, the above data demonstrate
that FERM2 suppresses SMC gene expression by pre-
venting SRF nuclear translocation.
FERM2 regulates EC gene expression through a post-
transcriptional mechanism
Conversely, we found that all the EC genes examined in
this study were inhibited by FERMT2 knockdown (sup-
plementary material, Figure S8B). We wondered if EC
gene expression was transcriptionally regulated by
FERM2. Luciferase activity assays with EC gene
(VWF and CDH5) promoter reporters showed that the
EC gene promoter activity was not regulated by
FERMT2 inhibition (Figure 4A), indicating that tran-
scriptional regulation is not behind EC gene regulation
by FERM2. Our mRNA stability assays with the tran-
scription inhibitor actinomycin D revealed that FERMT2
knockdown promoted both VWF and CDH5 mRNA
degradation (Figure 4B). To further explore the mecha-
nistic link between FERM2 and EC gene mRNA stabil-
ity, we re-scrutinized the FERM2 PPI network
(supplementary material, Figure S9) and found that there
is potential interaction between FERM2 and Y box bind-
ing protein 1 (YBOX1). Among many other important
functions, YBOX1 has been specifically recognized as
one of the major partners of mRNAs in the cytoplasm
and a key mRNA stabilizer [38]. We wondered if
FERM2 promotes mRNA stabilization of EC genes
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through YBOX1. Similar to SRF, we found no evidence
to support the notion that FERM2 regulates YBX1 gene
expression (Figure 3A). Proteomics analysis data also
showed that the YBOX1 protein level was not signifi-
cantly affected by miR-200c-3p overexpression (fold-
change = 1.21, p = 0.628). Instead, data from double
Figure 2 Legend on next page.
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immunofluorescence staining (supplementary material,
Figure S11) and PLA assays (Figure 4C) confirmed the
direct interaction between FERM2 and YBOX1, mainly
within the cytoplasm. Importantly, RIP assays showed
the direct binding of YBOX1 protein to VWF and
CDH5 mRNAs, and such binding was significantly
Figure 2. FERM2was identified as a target gene of miR-200c-3p during EndoMT. (A–C) FERM2 expression was down-regulated by miR-200c-
3p overexpression. HUVECs were infected with medium control (Ctrl), a scrambled negative control miRNA (Lenti-SCR) or miR-200c-3p over-
expression (Lenti-miR-200c) lentivirus, respectively. Infected cells were incubated with 5 ng/ml TGFβ1/TNFα for 4 days. Total RNAs and pro-
teins were harvested and subjected to label-free quantitative proteomics (A), western blot (B), and RT-qPCR (C) analysis, respectively. Volcano
plot in A showing the P values (−log10) against the fold-changes of protein expression levels (log2) in cells infected with Lenti-miR-200c-3p
versus Lenti-SCR. Triangles indicate the down-regulated proteins with their mRNA 3’-UTR containing one or more miR-200c-3p binding
sites(s). The data presented here are representative images (left panel in B) or mean  SEM of six (n = 6) independent experiments.
***p < 0.001 (versus Ctrl/SCR; one-way ANOVA with a Tukey’s post hoc test). (D) Two potential wild-type binding sites (BS1 and BS2) of
miR-200c-3p within FERMT2 3’-UTR as predicted by miRanda and their mutants (BS1/2mut) are depicted in this illustration. (E) Both binding
sites are required for FERM2 repression by miR-200c-3p. HUVECs infected with Lenti-SCR or Lenti-miR-200c were transfected with wild-
type FERMT2 3’-UTR reporter (WT), or the indicated single/combined binding site mutants [bindings site 1 (BS1mut), 2 (BS2mut), or the com-
binational mutations (BS1/2mut)], respectively. Luciferase activity assay was conducted at 48 h post-transfection. The data presented here are
mean  SEM of five independent experiments (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001 (versus SCR, Student’s t-test).
Figure 3. FERM2 suppresses SMC gene expression by interacting with and retaining SRF within cytoplasm. HUVECs infected with a non-
target (sh-NT) or FERMT2 gene-specific shRNA (sh-FERMT2) lentivirus were incubated with 5 ng/ml TGFβ1/TNFα for 4 days to induce
EndoMT. (A) RT-qPCR analysis of gene expression. (B) Proximity ligation assays (PLAs) using a pair of primary antibodies (or respective IgG
controls) as indicated to detect the in situ protein interactions of FERM2 with SRF in HUVECs undergoing EndoMT. (C) SMC gene promoter
activity assays showed that SRF binding sites(s) are required for FERM2-mediated SMC gene suppression. HUVECs infected with sh-NT or sh-
FERM2 lentivirus were transfected with wild-type SMC gene promoters (pGL3-ACTA2/TAGLN) or their SRF binding site mutants
(pGL3-ACTA2/TAGLN-SRFmut), respectively. Luciferase activity assay was conducted at 48 h post-transfection. (D) FERMT2 knockdown
increased the binding and enrichment of SRF to SMC gene promoters. ChIP assays were performed using antibody against SRF or normal
IgG, respectively, as described in the Materials and methods section. Quantitative PCR amplifications of the adjacent regions without SRF
binding sites (CArG element) were included as an additional control for specific promoter DNA enrichment. The data presented here are rep-
resentative images (B) or mean  SEM (A, C, D) of five (n = 5) independent experiments. **p < 0.05 (versus sh-NT); #p < 0.05, ##p < 0.01
(versus promoter DNA without CArG region). Student’s t-test (A) or two-way ANOVA with a Tukey’s post hoc test (C, D) was used for statistical
analysis, respectively.
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inhibited by FERMT2 knockdown (Figure 4D). Hence,
these data reveal that FERM2 increases EC mRNA sta-
bility by working in concert with YBOX1.
Arterial inhibition of miR-200c-3p decreases
neointimal hyperplasia in grafted aortas
As mentioned previously, EndoMT is one of the major
contributors to vascular graft stenosis [12]. To
investigate whether miR-200c-3p plays a role in
EndoMT in the context of vascular graft remodelling, a
well-established aortic isograft transplantation model
[33,34] was carried out between female C57BL/6J and
male cadherin 5 (Cdh5)-CreERT2 × Rosa26-tdTomato
mice (supplementary material, Figure S12A). Cdh5-
CreERT2 × Rosa26-tdTomato mice with or without four
pulses of tamoxifen administration were used in the iso-
grafting model for inducible and irreversible labelling
Figure 4. FERM2 regulates EC gene expression by preventing their mRNA decay via interacting with DNA/RNA binding protein YBX1. (A) VWF
and CDH5 gene promoter activity was not regulated by FERM2. (B) VWF and CDH5 mRNA degradation was increased by FERMT2 inhibition.
HUVECs infected with a non-target (sh-NT) or FERMT2 gene-specific shRNA (sh-FERM2) lentivirus were treated with the transcription inhib-
itor (actinomycin D, ActD, 1 μg/ml) for the indicated times. The VWF/CDH5mRNA arbitrary unit at 0 h for both groups was set as 1.0, and at
other time points was calculated accordingly. (C) Proximity ligation assays (PLAs) showed the in situ protein interactions of FERM2 with
YBOX1 in HUVECs. (D) RNA immunoprecipitation (RIP) assays were conducted in HUVECs infected with sh-NT or sh-FERM2 lentivirus using
antibody against YBOX1 or normal IgG, respectively. Immunoprecipitated RNAs were subjected to RT-qPCR with the indicated gene primers.
The data presented here are representative images (C) or mean  SEM (A, B, D) of five (n = 5) independent experiments. *p < 0.05, **p < 0.01
(versus sh-NT); #p < 0.05, ##p < 0.01 (versus 0 h or Intron). Two-way ANOVA with a Tukey’s post hoc test (B) or Student’s t-test (D) was used
for statistical analysis, respectively.
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and tracing of ECs (CADH5+ cells) and their progeny in
aortic graft arteriosclerosis (supplementary material,
Figure S12A). Immunostaining confirmed the abundant
accumulation of tdTomato+/SMαA+ cells in the neointi-
mal lesions (supplementary material, Figure S12B),
indicating that the donor ECs underwent an EndoMT
process and that this process (or ECs undergoing
EndoMT) contributed to isograft-induced neointima for-
mation. Importantly, no tdTomato/RFP signals were
observed in the grafted aortas in the absence of tamoxi-
fen, demonstrating no ‘leak’ of the Cdh5-
CreERT2 × Rosa26-tdTomato system (supplementary
material, Figure S12C).
After confirming the contribution of EndoMT to
isograft-induced neointima formation, we decided to
examine the expression profile of miR-200c-3p in graft
restenosis. We found that miR-200c-3p expression
peaked at day 7 post-grafting and gradually decreased
thereafter (Figure 5A), indicating the involvement of
miR-200c-3p in isograft-induced neointima formation.
To confirm such involvement, locked nucleic acid
(LNA)-modified oligonucleotides (LNA-SCR, a scram-
bled negative control, or LNA-miR-200c, for miR-
200c-3p specific inhibition) were directly infused into
the lumen of the aortas immediately after harvesting to
induce local endothelium transfection. Two weeks after
grafting, tdTomato+ cells were isolated from the grafted
aortas and subjected to RT-qPCR analysis. The data
shown in Figure 5B confirmed that miR-200c-3p expres-
sion was successfully inhibited in donor ECs and their
progeny. Consistent with this, we observed increased
expression of Fermt2 along with EC markers (Pecam1
and Cdh5), but decreased expression of mesenchymal/
SMC genes (Acta2, Tagln, and Cdh2) in donor ECs of
the grafted aorta transfected with LNA-miR-200c
(Figure 5B), demonstrating a role for miR-200c-3p in
EndoMT in the context of aortic graft remodelling. This
was further supported by double immunofluorescence
staining of the grafted aortas using antibodies against
RFP/tdTomato and SMαA (Figure 5C,D). Similar to
our in vitro observation, we observed that SRF protein
was mainly accumulated within cell nuclei in the aortas
treated with LNA-SCR, but their main cellular location
was cytoplasm in the aortas infected with LNA-miR-
200c (supplementary material, Figure S13). Importantly,
we observed an approximately 70% decrease in
neointima formation in grafted aortas treated with
LNA-miR-200c, compared with the aortas treated with
LNA-SCR (Figure 5E,F).
Expression of the miR-200c-3p/FERMT2 regulatory
axis in human arteries
We have so far demonstrated that the miR-200c-3p/
FERM2 regulatory axis plays a critical role in EndoMT
and aortic graft restenosis. To further validate these find-
ings in a clinical setting, we first conducted double
immunofluorescence assays in human femoral arterial
specimens collected in our recent study [35]. Immunos-
taining showed a higher number of VWF+/SMαA+ cells,
suggestive of cells undergoing EndoMT, in the diseased
arteries, compared with the healthy arteries (Figure 6A,B
and supplementary material Figure S14). Similarly, the
cDNAs generated in the same study [35] were used for
examining the expression levels of miR-200c-3p and
FERMT2 in these femoral arterial specimens by RT-
qPCR analysis. Compared with healthy arteries, an
increased expression level of miR-200c-3p, but a
decreased expression level of the FERMT2 gene, was
observed in the diseased arteries (Figure 6C). Addition-
ally, we found a significant inverse relationship between
miR-200c-3p and FERMT2 gene expression levels in
both healthy and diseased femoral arterial specimens
(Figure 6D).
Discussion
The major cause for vascular graft loss/failure after
CABG is accelerated coronary allograft arteriosclerosis,
characterized by neointimal hyperplasia consisting
mainly of SMC-/myofibroblast-like cells. However, the
cellular origins of these neointimal cells are still under-
going extensive debate [39,40]. EndoMT has recently
been suggested as an important driver of neointima for-
mation in a murine transplant arteriopathy model and
in rejecting human transplant lesions [6]. In agreement
with this report, using an inducible genetic lineage trac-
ing (Cdh5-CreERT2 × Rosa26-tdTomato mice) system
and aortic isograft model, we provide genetic lineage
tracing evidence that ECs undergoing EndoMT are crit-
ical contributors of neointimal cells in mouse isograft
transplantation. Our immunostaining data also clearly
provide evidence for the existence and involvement of
EndoMT in human arteriosclerosis. Moreover, we have
advanced our knowledge about the underlying molecu-
lar mechanisms of EndoMT by reporting a regulatory
role for miR-200c-3p in promoting EndoMT in vitro
and in vivo. Data generated from our mechanistic studies
confirmed FERMT2 as a functional target gene of miR-
200c-3p in the context of EndoMT. Furthermore, we
also provide clear evidence to support the notion that
miR-200c-3p suppresses FERMT2 gene expression in
the grafted aortas, triggers the EndoMT process, and
promotes aortic graft restenosis. Hence, the use of a
miR-200c-3p inhibitor to dampen EndoMT processes
in vascular grafts may be a reasonable interventional
approach for vascular graft loss/failure after CABG
(supplementary material, Figure S15).
An inhibitory role for the whole miR-200 family in
EMT and its inverse processes have been well estab-
lished [28]. Recently, two miR-200 family members
(miR-200a [41] and miR-200b [42]) have been reported
to play a similar inhibitory role in EndoMT, while the
functional involvement of another three members
(miR-141, miR-200c, and miR-429) in EndoMT
remains to be seen. To our surprise, in this study we have
documented a promotive effect of miR-200c-3p on
EndoMT and aortic graft remodelling. Through miR-
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200c-3p gain/loss-of function analyses, we first demon-
strated that miR-200c-3p promotes EndoMT, as evi-
denced by decreased expression of EC genes, increased
expression of SMC-like or mesenchymal genes, as well
as acquired SMC-like or mesenchymal cell morphology
and function, and a simultaneous loss of EC functional
Figure 5 Legend on next page.
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characteristics (Figure 1 and supplementary material,
Figures S3–S6). Importantly, by using a vascular graft-
induced neointima formation model and through local
incubation of the endothelium of the grafts with LNA-
miR-200c, we further demonstrated that miR-200c-3p
inhibition reduces EndoMT and inhibits neointimal
hyperplasia in the grafted arteries, showing that miR-
200c-3p is a potential therapeutic agent in vascular
grafting-induced restenosis. Therefore, findings from
this study and previous studies [30,43] indicate that
miR-200c-3p exerts an antagonist role in EMT (inhibit-
ing) and EndoMT (promoting), and that miR-200c-3p
can play divergent roles in different biological pro-
cesses. Consequently, caution should be taken when
considering the clinical applications for treating distinct
human diseases through modulation of miR-200c-3p
signalling.
A new finding from this study reveals that FERMT2 is
the functional and authentic target gene of miR-200c-3p
in the context of EndoMT and aortic graft remodelling.
Although a handful of miR-200c-3p target genes have
been reported in various cellular contexts and diseases
[29,30], we have now provided several lines of evidence
to support the notion that FERMT2 is a novel target gene
of miR-200c-3p during EndoMT, and have demon-
strated that miR-200c-3p promotes EndoMT by target-
ing FERMT2. Our finding aligns perfectly with the
functional implications of FERM2 in EMT and other
cellular functions. Global deletion of the FERMT2 gene
causes embryonic lethality [44] and severe abnormalities
of heart development [45,46], and genetic deletion of
FERMT2 at late gestation or in adult cardiac myocytes
results in heart failure and premature death because of
enlargement of the heart and extensive fibrosis [47].
Later studies reported a role for FERM2 in epithelial cell
phenotype modification [48], pathological and develop-
mental angiogenesis [49], renal tubular cell plasticity
[50] and renal fibrosis [51], and platelet responses and
haemostasis [52]. It has also been reported that FERM2
promotes cancer angiogenesis and tumour progression
[53], or breast cancer metastasis [54] by modulating
EMT, and serves as a mechano-responsive protein to
link mechano-environmental signalling to proline
metabolism, promoting tumour growth [55]. A critical
role for FERM2 in the control of adipogenesis, lipid
metabolism, and bone homeostasis [56], chondrocyte
differentiation program and chondrogenesis [57], and
myogenic [58] as well as mesenchymal stem cell differ-
entiation [59] has also been reported in recent studies.
Another novel finding in this study is the role of
FERM2 in regulating SMC and EC gene expression
through a transcriptional repression and post-
transcriptional activation mechanism, respectively. Spe-
cifically, we demonstrated that FERM2 transcriptionally
represses SMC-specific gene expression by interacting
with SRF and modulating its cellular location during
EndoMT. Increasing evidence has suggested that
FERM2 regulates gene expression through its direct
interaction with and by stabilizing one or more partner
proteins, thus controlling their associated signalling
pathways. It has been reported that FERM2 regulates
cell adhesion and spreading by recruiting and interacting
with paxillin [60], Arp2/3 [61], myosin light-chain
kinase [59], and integrin-linked kinase [62], respec-
tively. FERM2 has been shown to directly interact with
and stabilize DNMT1, and to increase the occupancy
of DNMT1 at the E-cadherin (CDH1) promoter, thereby
suppressing E-cadherin expression [63]. It also interacts
with vascular endothelial cadherin-based complexes to
support vascular barrier integrity [64]. FERM2 regulates
integrin outside-in signalling by direct binding with
actin [65], talin/paxillin [66], α-actinin-2 [67], and/or
integrin β1 [67]/β3 [68]. Interestingly, FERM2 forms a
transcriptional complex with β-catenin and TCF4 to
enhance Wnt signalling [69], and physically interacts
with both TGFβ type I receptor and Smad3 to activate
TGF-β/Smad signalling [51], respectively. Moreover,
the underlying mechanism of controlling EC endocyto-
sis and recycling of CD39 and CD73 during haemostasis
was attributed to the direct interaction of FERM2 with
clathrin heavy chain [52]. In this study, we provided
clear evidence for the first time to show that FERM2
could directly interact with SRF and retain it within the
cytoplasm in normal ECs. However, such interaction is
disrupted when these ECs undergo EndoMT or when
FERM2 protein is removed/reduced by miR-200c-3p
expression. Consequently, SRF is released from the
FERM2/SRF complex within the cytoplasm, and
Figure 5.miR-200c-3p inhibition in grafted aortas reduces EndoMT and prevents neointima formation in the grafts. (A) Increased expression
of miR-200c-3p in grafted aortas. Total RNAs were harvested from non-implanted (used as sham surgery) and post-implanted aortas at the
indicated times and subjected to RT-qPCR analyses. The data presented here are mean  SEM of five independent experiments (aortas from
3–5 mice were pooled for each experiment, n = 5 experiments). *p < 0.05, **p < 0.01, ***p < 0.001 (versus sham; one-way ANOVA with a
Tukey’s post hoc test). (B) miR-200c-3p inhibition prevents EndoMT in the grafted aorta. Two weeks after grafting, the grafted aortas from
6–8 mice were harvested, pooled, and prepared for cell sorting. Total RNAs were extracted from tdTomato+ cells isolated from the grafted
aortas treated with medium only (Sham), a scrambled negative control (LNA-SCR), or LNA-miR-200c-3p (LNA-miR-200c) inhibitor, respec-
tively, and subjected to RT-qPCR analysis. The data presented here are mean  SEM of five independent experiments (n = 5). *p < 0.05
(one-way ANOVA with a Tukey’s post hoc test). (C, D) Decreased numbers of cells underwent EndoMT in the grafted aortas treated with
LNA-miR-200c. Four weeks after grafting, grafted aortas were harvested and subjected to immunostaining. The data presented here are
the representative images (C) and the quantitative results of tdTomato+/SMA+ (cells underwent EndoMT) (D) from 11 (LNA-SCR) and
12 (LNA-miR-200c) mice, respectively. Note: arrows in C indicate cells that underwent EndoMT. (E, F) miR-200c-3p local inhibition decreases
neointimal hyperplasia in vascular grafts. Four weeks after grafting, grafted aortas were harvested and prepared for H&E staining analyses.
Representative images (E) and morphological characteristics (F) including neointimal area and neointimal/media (N/M) ratio of the implanted
aortas from 11 (LNA-SCR) and 12 (LNA-miR-200c) mice, respectively, are presented here. **p < 0.01 (versus LNA-SCR, Student’s t-test).
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Figure 6. Detection of EndoMT and miR-200c-3p/FERM2 regulatory axis in human arteries. Human femoral arterial specimens from patients
with (diseased FA, DFA) or without (healthy FA, HFA) peripheral arterial diseases who underwent leg amputation were collected and subjected
to immunostaining assays (A, B) and RT-qPCR analyses (C, D), respectively. (A, B) Higher incidence of EndoMT was detected in DFA. The data
presented here are the representative images (A) and the quantitative results of VWF+/SMαA+ (suggestive of EndoMT) (B) from 15 patients
(n = 15 patients for both groups). Student’s t-test. Note: the arrows in A indicate cells undergoing EndoMT. (C) miR-200c-3p and FERMT2
gene expression in human arteries. A Mann–Whitney U-test was applied for statistical analysis. (D) Spearman’s rank correlation coefficient
analyses of the expression levels of miR-200c-3p and FERMT2 in human femoral arterial specimens. N = 15 from each group.
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translocates into the nuclei, thereby triggering the SMC
gene transcription program [70] and promoting
EndoMT.
With regard to EC gene regulation by FERM2 during
EndoMT, several convincing lines of evidence have
been described and presented in this study to support
the mechanistic findings that FERM2 controls EC gene
expression through a post-transcriptional mechanism.
We documented a positive relationship between FERM2
expression levels and EC gene expression and presented
strong evidence to show that FERM2 controls both VWF
and CDH5 mRNA stability. We further confirmed an in
situ interaction between FERM2 and YBOX1 proteins,
and demonstrated direct binding and enrichment of
VWF and CDH5 mRNAs to YBOX1. YBOX1 is a
DNA/RNA-binding protein controlling gene expression
by regulating mRNA stabilization and splicing [71,72].
Apart from its apparent function in gene regulation, stud-
ies reported a regulatory role of YBOX1 in EMT
[73,74], mesenchymal–endothelial transition [75], and
EC function [76]. Interestingly, the secreted form of
YBOX1 has also been implicated in controlling cell pro-
liferation and migration [77]. We have now documented
a novel role for YBOX1 in the regulation of EC gene
expression and/or EndoMT by stabilizing EC gene tran-
scripts. It has been suggested that YBOX1 regulates the
stability of its target mRNA by recruiting ELAVL1 [72]
or another RNA binding protein, nucleolin [71]. There-
fore, further studies are warranted to investigate whether
ELAVL1, nucleolin, or other co-regulators are required
for the preventive effect of the FERM2/YBOX1 complex
on VWF/CDH5 mRNA degradation during EndoMT.
Apart from the validated target gene, FERM2, an addi-
tional 40 proteins were found to be down-regulated by
miR-200c-3p overexpression duringEndoMT in our proteo-
mics analyses (Figure 2A and supplementary material,
Figure S7A). Among them, 23 genes were predicted to con-
tain one or more miR-200c-3p binding sites, and thus repre-
sent likely candidates which may potentially function as
target genes for miR-200c-3p. As expected, some of them
(e.g. ZEB1, KLF9, SUZ12) have been reported as target
genes of miR-200c-3p in EMT and other biological pro-
cesses, as summarized in two reviews [29,30]. However,
the functional implications of these genes in EndoMT and
vascular grafting-induced remodelling remain to be seen.
Taken together, we have demonstrated that miR-200c-
3p plays an important role in EndoMT and aortic
isograft-induced restenosis and have identified FERM2 as
the functional downstream target of miR-200c-3p in the
context of EndoMT and vascular graft remodelling. These
findings may provide novel insights into the pathogenesis
of neointimal hyperplasia in the vascular grafts and have
further potential therapeutic implications for vascular dis-
eases (supplementary material, Figure S15). Since
EndoMT plays a key role in the pathogenesis of various
diseases, modulating the miR-200c-3p/FERM2 regulatory
axis in the context of EndoMT may represent a broadly
effective therapy strategy against a host of other fibrotic
disorders including pulmonary, intestinal, cardiac, and kid-
ney fibrosis.
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